Dr. Arif Hussain, MD

Dr. Hussain practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Hussain's NPI, 1770546830, was assigned on April 10, 2006. Dr. Hussain graduated from Howard University College of Medicine in 1980. Dr. Hussain holds Maryland license D33759.

Dr. Hussain's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Hussain's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Hussain is also affiliated with TidalHealth Atlantic. The medical group on file is University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hussain practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Hussain's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hussain is licensed in Maryland.

CMS data shows 497 Medicare services from Dr. Hussain across 4 procedure codes in 2024, for 177 Medicare patients. Medicare paid $40,388 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 177 Medicare patients who saw Dr. Hussain in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have cancer, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hussain's median patient age at 71, with 14% women.

In 2024, Dr. Hussain wrote 1,049 Medicare Part D claims for 105 patients. 87% of them were for generic drugs. CMS names the drug for 874 of them, across 20 drugs with 11 or more claims each, at $2,284,323 in total drug cost. In 2023, CMS named 639 claims across 12 drugs.

Dr. Hussain accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hussain as offering telehealth.

Dmand AI links 199 papers to Dr. Hussain, published from 2005 to 2025. 2022 was the busiest year, with 22. The most frequent topics are Prostatic Neoplasms, Gene Expression Regulation, Neoplastic and HeLa Cells. Dr. Hussain has published most often in Curr Opin Oncol. Dr. Hussain's most frequent co-authors are Young Kwok, MD, Janakiraman Subramanian, MD and Heather D. Mannuel, MD.

Dmand AI links Dr. Hussain to 7 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Prostatic Neoplasms and Kidney Neoplasms. Calithera Biosciences, Inc sponsors the most, 2. Open Payments lists research payments to Dr. Hussain that name 1 trial.

CMS Open Payments shows 147 general payments to Dr. Hussain from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $37,508. It also lists 7 research payments totaling $6,181 from 2020 to 2025, naming 1 clinical trial.

Dr. Hussain graduated from Howard University College of Medicine in 1980.